Central nervous system therapeutics - Antares Pharma

Drug Profile

Central nervous system therapeutics - Antares Pharma

Alternative Names: Quickshot® M; Vibex® QS M

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Antares Pharma
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical CNS disorders

Most Recent Events

  • 08 Sep 2016 Antares Pharma announces intention to submit NDA (Antares Pharma pipeline, September 2016)
  • 13 Oct 2015 Preclinical trials in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top